1. Search Result
Search Result
Results for "

pumps

" in MedChemExpress (MCE) Product Catalog:

174

Inhibitors & Agonists

2

Screening Libraries

1

Fluorescent Dye

3

Biochemical Assay Reagents

14

Peptides

26

Natural
Products

33

Isotope-Labeled Compounds

5

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-13662S

    AG-1749-d4

    Proton Pump Bacterial Inflammation/Immunology Cancer
    Lansoprazole-d4 is a deuterium labeled Lansoprazole. Lansoprazole is a proton pump inhibitor which prevents the stomach from producing acid[1].
    Lansoprazole-d4
  • HY-15134

    OC 144-093; OC 144093

    P-glycoprotein Cancer
    ONT-093 is a potent inhibitor of P-glycoprotein pump. ONT-093 has the potential for the research cancer diseases .
    ONT-093
  • HY-Y1777

    Others Infection
    2-Phenylacetophenone has broad-spectrum efflux pump inhibition activity. 2-Phenylacetophenone is a benzoin derivative used as a photoinitiator in vinyl polymerization .
    2-Phenylacetophenone
  • HY-101664

    IY-81149

    Proton Pump TOPK Inflammation/Immunology Cancer
    Ilaprazole (IY-81149) is an orally active proton pump inhibitor. Ilaprazole irreversibly inhibits H +/K +-ATPase in a dose-dependent manner with an IC50 of pump inhibitory activity of 6 μM in rabbit parietal cell preparation. Ilaprazole is used for the research of gastric ulcers. Ilaprazole is also a potent TOPK (T-lymphokine-activated killer cell-originated protein kinase) inhibitor .
    Ilaprazole
  • HY-156753

    Others Cancer
    NorA-IN-1 (Compound 16) is a NorA inhibitor. NorA-IN-1 inhibits NorA efflux pump in everted membrane vesicles. NorA-IN-1 can be used for research of multidrug resistance .
    NorA-IN-1
  • HY-149811

    Bacterial Parasite Infection
    Efflux pump-IN-3 is an AcrB efflux pump inhibitor, with ability to potentiate the effect of antibiotics. Efflux pump-IN-3 inhibits Nile Red (a known substrate of AcrB) efflux. Efflux pump-IN-3 does not disrupts the bacterial outer membrane nor display toxicity in a nematode model .
    AcrB-IN-3
  • HY-149812

    Bacterial Parasite Infection
    Efflux pump-IN-4 is an AcrB efflux pump inhibitor, with ability to potentiate the effect of antibiotics. Efflux pump-IN-4 inhibits Nile Red (a known substrate of AcrB) efflux. Efflux pump-IN-4 does not disrupts the bacterial outer membrane nor display toxicity in a nematode model .
    AcrB-IN-4
  • HY-116102

    Na+/K+ ATPase Infection
    Laurinterol is a Na +/K +-ATPase sodium-potassium ion pump inhibitor that can be isolated from Laurencia johnstonii eliminates .
    Laurinterol
  • HY-123754

    Proton Pump Inflammation/Immunology
    AGN-201904 is a proton pump inhibitor. AGN-201904 is an omeprazole prodrug that can delay aging and can be used to prevent and treat peptic ulcers .
    AGN-201904
  • HY-17507E

    Proton Pump Bacterial Infection
    S-Pantoprazole (sodium trihydrate) is related to Pantoprazole (HY-17507) that plays an important roles in gastric acid secretion disorder-related diseases, or as proton pump inhibitor .
    S-Pantoprazole sodium trihydrate
  • HY-N2947

    P-glycoprotein Infection Inflammation/Immunology
    Boeravinone B, a dual inhibitor of NorA bacterial efflux pump of Staphylococcus aureus and human P-Glycoprotein, reduces the biofilm formation and intracellular invasion of bacteria. Boeravinone B act as anti-aging and anti-apoptosis phyto-molecules during oxidative stress .
    Boeravinone B
  • HY-139557

    JP-1366

    Proton Pump Inflammation/Immunology
    Zastaprazan (JP-1366) is a proton pump inhibitor (WO2018008929). Zastaprazan can be used for the research of gastrointestinal inflammatory diseases or gastric acid-related diseases .
    Zastaprazan
  • HY-101664R

    Proton Pump TOPK Inflammation/Immunology Cancer
    Ilaprazole (Standard) is the analytical standard of Ilaprazole. This product is intended for research and analytical applications. Ilaprazole (IY-81149) is an orally active proton pump inhibitor. Ilaprazole irreversibly inhibits H +/K +-ATPase in a dose-dependent manner with an IC50 of pump inhibitory activity of 6 μM in rabbit parietal cell preparation. Ilaprazole is used for the research of gastric ulcers. Ilaprazole is also a potent TOPK (T-lymphokine-activated killer cell-originated protein kinase) inhibitor .
    Ilaprazole (Standard)
  • HY-145327

    Na+/K+ ATPase Parasite Infection
    Antimalarial agent 7 is a potent inhibitor of PfATP4. PfATP4 is an essential ion pump on the parasite surface. Antimalarial agent 7 has the potential for the research of human malaria parasite, Plasmodium falciparum .
    Antimalarial agent 7
  • HY-163473

    Bacterial Infection
    IITR08367 is a potent effector pump Acinetobacter baumannii Fosfomycin Efflux pump (AbaF) inhibitor for enhancing the antimicrobial activity of Fosfomycin (HY-B1075A) against Acinetobacter baumannii. IITR08367 acts by interfering with Fosfomycin/H + reverse transporter activity. .
    IITR08367
  • HY-109079A

    DWP14012 hydrochloride; Fexuprazan hydrochloride

    Proton Pump Metabolic Disease
    Abeprazan hydrochloride (DWP14012 hydrochloride) is a potassium-competitive acid blocker. Abeprazan hydrochloride inhibits H +, K +- ATPase by reversible potassium-competitive ionic binding with no acid activation required. Abeprazan hydrochloride is developed as a potential alternative to proton pump inhibitor for the treatment of acid-related diseases .
    Abeprazan hydrochloride
  • HY-109079

    DWP14012; Fexuprazan

    Proton Pump Metabolic Disease
    Abeprazan (DWP14012) is a potassium-competitive acid blocker. Abeprazan inhibits H +, K +- ATPase by reversible potassium-competitive ionic binding with no acid activation required. Abeprazan is developed as a potential alternative to proton pump inhibitor for the treatment of acid-related diseases .
    Abeprazan
  • HY-B2145

    IY-81149 sodium

    Proton Pump TOPK Inflammation/Immunology Cancer
    Ilaprazole (IY-81149) sodium is an orally active proton pump inhibitor. Ilaprazole sodium irreversibly inhibits H +/K +-ATPase in a dose-dependent manner with an IC50 of 6 μM in rabbit parietal cell preparation. Ilaprazole sodium is used for the research of gastric ulcers. Ilaprazole sodium is also a potent TOPK (T-lymphokine-activated killer cell-originated protein kinase) inhibitor .
    Ilaprazole sodium
  • HY-13100

    Proton Pump Metabolic Disease
    PF 03716556 is a potent, selective, competitive and reversible acid pump (H +,K +-ATPase) antagonist with pIC50s of 6.026, 6.038 and 6.009 for porcine, canine, and human recombinant gastric H +,K +-ATPase, respectively. PF 03716556 is inactive against other receptors, ion channels, and enzymes. PF 03716556 has the potential for gastroesophageal reflux disease research .
    PF 03716556
  • HY-149810

    Bacterial Parasite Infection
    AcrB-IN-2 is an AcrB efflux pump inhibitor, with ability to potentiate the effect of antibiotics. AcrB-IN-22 inhibits Nile Red (a known substrate of AcrB) efflux.AcrB-IN-2 does not disrupts the bacterial outer membrane nor display toxicity in a nematode model .
    AcrB-IN-2
  • HY-D1608

    Calcium Channel Others
    BODIPY FL Thapsigargin is a potent green fluorescent dye. BODIPY FL Thapsigargin inhibits intracellular SERCA-type Ca2+ pumps present in the sarcoplasmic/endoplasmic reticulum. BODIPY FL Thapsigargin used for investigation of thapsigargin binding sites in live cells .
    BODIPY FL Thapsigargin
  • HY-B0656
    Rabeprazole
    3 Publications Verification

    LY307640

    Proton Pump Apoptosis Bacterial Inflammation/Immunology Cancer
    Rabeprazole (LY307640) is a second-generation proton pump inhibitor (PPI) that irreversibly inactivates gastric H +/K +-ATPase. Rabeprazole induces apoptosis. Rabeprazole acts as an uridine nucleoside ribohydrolase (UNH) inhibitor with an IC50 of 0.3 μM. Rabeprazole can be used for the research of gastric ulcerations and gastroesophageal reflux .
    Rabeprazole
  • HY-B0656A
    Rabeprazole sodium
    3 Publications Verification

    LY307640 sodium

    Proton Pump Apoptosis Bacterial Inflammation/Immunology Cancer
    Rabeprazole sodium (LY307640 sodium) is a second-generation proton pump inhibitor (PPI) that irreversibly inactivates gastric H +/K +-ATPase. Rabeprazole sodium induces apoptosis. Rabeprazole sodium acts as an uridine nucleoside ribohydrolase (UNH) inhibitor with an IC50 of 0.3 μM. Rabeprazole sodium can be used for the research of gastric ulcerations and gastroesophageal reflux .
    Rabeprazole sodium
  • HY-B0656S

    LY307640-d4

    Proton Pump Apoptosis Inflammation/Immunology Cancer
    Rabeprazole-d4 is a deuterium labeled Rabeprazole. Rabeprazole is a second-generation proton pump inhibitor (PPI) that irreversibly inactivates gastric H+/K+-ATPase. Rabeprazole induces apoptosis. Rabeprazole acts as an uridine nucleoside ribohydrolase (UNH) inhibitor with an IC50 of 0.3 μM. Rabeprazole can be used for the research of gastric ulcerations and gastroesophageal reflux[1][2][3].
    Rabeprazole-d4
  • HY-P1075
    CALP3
    2 Publications Verification

    Calcium Channel Neurological Disease Cancer
    CALP3, a Ca 2+-like peptide, is a potent Ca 2+ channel blocker that activates EF hand motifs of Ca 2+-binding proteins. CALP3 can functionally mimic increased [Ca 2+]i by modulating the activity of Calmodulin (CaM), Ca 2+ channels and pumps. CALP3 has the potential in controlling apoptosis in diseases such as AIDS or neuronal loss due to ischemia .
    CALP3
  • HY-P5422

    Calcium Channel Others
    Caloxin 3A1 is a biological active peptide. (This peptide belongs to caloxins, the extracellular plasma membrane (PM) Ca2+ pump inhibitors. Caloxin 3A1 inhibits plasma membrane calcium pumps (PMCAs) but not the sarcoplasmic reticulum Ca2+-pump. This peptide does not inhibit formation of the acylphosphate intermediate from ATP.)
    Caloxin 3A1
  • HY-B0656R

    Proton Pump Apoptosis Bacterial Inflammation/Immunology Cancer
    Rabeprazole (Standard) is the analytical standard of Rabeprazole. This product is intended for research and analytical applications. Rabeprazole (LY307640) is a second-generation proton pump inhibitor (PPI) that irreversibly inactivates gastric H +/K +-ATPase. Rabeprazole induces apoptosis. Rabeprazole acts as an uridine nucleoside ribohydrolase (UNH) inhibitor with an IC50 of 0.3 μM. Rabeprazole can be used for the research of gastric ulcerations and gastroesophageal reflux .
    Rabeprazole (Standard)
  • HY-B0656AS2

    LY307640-d4 potassium

    Apoptosis Bacterial Proton Pump Isotope-Labeled Compounds Inflammation/Immunology Cancer
    Rabeprazole-d4 potassium is deuterated labeled Rabeprazole sodium (HY-B0656A). Rabeprazole sodium (LY307640 sodium) is a second-generation proton pump inhibitor (PPI) that irreversibly inactivates gastric H +/K +-ATPase. Rabeprazole sodium induces apoptosis. Rabeprazole sodium acts as an uridine nucleoside ribohydrolase (UNH) inhibitor with an IC50 of 0.3 μM. Rabeprazole sodium can be used for the research of gastric ulcerations and gastroesophageal reflux .
    Rabeprazole-d4 potassium
  • HY-N1423
    Glycocholic acid
    1 Publications Verification

    Endogenous Metabolite Cancer
    Glycocholic acid is a bile acid with anticancer activity, targeting against pump resistance-related and non-pump resistance-related pathways .
    Glycocholic acid
  • HY-P1075A

    Calcium Channel Neurological Disease Cancer
    CALP3 TFA, a Ca 2+-like peptide, is a potent Ca 2+ channel blocker that activates EF hand motifs of Ca 2+-binding proteins. CALP3 TFA can functionally mimic increased [Ca 2+]i by modulating the activity of Calmodulin (CaM), Ca 2+ channels and pumps. CALP3 TFA has the potential in controlling apoptosis in diseases such as AIDS or neuronal loss due to ischemia .
    CALP3 TFA
  • HY-N1423A
    Glycocholic acid sodium
    1 Publications Verification

    Endogenous Metabolite Others Cancer
    Glycocholic acid sodium is an orally active bile acid with anticancer activity, targeting against pump resistance-related and non-pump resistance-related pathways .
    Glycocholic acid sodium
  • HY-16215

    G-202

    Drug-Linker Conjugates for ADC Cancer
    Mipsagargin (G-202) is a novel thapsigargin-based targeted proagent consisting of a prostate-specific membrane antigen (PSMA)-specific peptide coupled to an analog of the potent sarcoplasmic/endoplasmic reticulum calcium adenosine triphosphatase (SERCA) pump inhibitor Thapsigargin (HY-13433). Mipsagargin is activated by PSMA-mediated cleavage of an inert masking peptide. Mipsagargin has the potential for refractory, advanced or metastatic solid tumours research .
    Mipsagargin
  • HY-N1423S1

    Isotope-Labeled Compounds Endogenous Metabolite Cancer
    Glycocholic acid-d5 is the deuterium labeled Glycocholic acid. Glycocholic acid is a bile acid with anticancer activity, targeting against pump resistance-related and non-pump resistance-related pathways .
    Glycocholic acid-d5
  • HY-13100A

    Others Metabolic Disease
    (S)-PF 03716556 is a K+-competitive acid blocker with gastric acid pump inhibitory activity. (S)-PF 03716556 can be used to inhibit disease states mediated by acid pump inhibitory activity .
    (S)-PF 03716556
  • HY-19223

    BY-841

    Proton Pump Inflammation/Immunology
    Pumaprazole is a reversible proton pump antagonist.
    Pumaprazole
  • HY-N1423S

    Endogenous Metabolite Cancer
    Glycocholic acid-d4 is the deuterium labeled Glycocholic acid. Glycocholic acid is a bile acid with anticancer activity, targeting against pump resistance-related and non-pump resistance-related pathways[1].
    Glycocholic acid-d4
  • HY-131846

    6-Chloropurine 5'-ribonucleotide

    Others Others
    6-Cl-5'-PuMP is a reactive analogue of adenosine 5’-O-monophosphate (5’-AMP), and is suitable for modifying position 6 using various nucleophiles .
    6-Cl-5'-PuMP
  • HY-N1423R

    Endogenous Metabolite Cancer
    Glycocholic acid (Standard) is the analytical standard of Glycocholic acid. This product is intended for research and analytical applications. Glycocholic acid is a bile acid with anticancer activity, targeting against pump resistance-related and non-pump resistance-related pathways .
    Glycocholic acid (Standard)
  • HY-400540

    Padoprazan

    Proton Pump Inflammation/Immunology
    Padoprazanum (Padoprazan) is a proton pump inhibitor .
    Padoprazanum
  • HY-15295
    Vonoprazan Fumarate
    5 Publications Verification

    TAK-438

    Proton Pump Metabolic Disease
    Vonoprazan Fumarate (TAK-438), a proton pump inhibitor (PPI), is a potent and orally active potassium-competitive acid blocker (P-CAB), with antisecretory activity. Vonoprazan Fumarate inhibits H +,K +-ATPase activity in porcine gastric microsomes with an IC50 of 19 nM at pH 6.5. Vonoprazan Fumarate is developed for the research of acid-related diseases, such as gastroesophageal reflux disease and peptic ulcer disease .
    Vonoprazan Fumarate
  • HY-G0007

    Omeprazole sulphone

    Drug Metabolite Infection Cancer
    Omeprazole sulfone is a metabolite of Omeprazole, which is a proton pump inhibitor.
    Omeprazole sulfone
  • HY-101444A
    PAβN dihydrochloride
    5+ Cited Publications

    MC-207,110 dihydrochloride; Phe-Arg-β-naphthylamide dihydrochloride

    Bacterial Infection
    PAβN dihydrochloride (MC-207110 dihydrochloride) is an efflux pump inhibitor.
    PAβN dihydrochloride
  • HY-100007A

    TAK-438 hydrochloride

    Proton Pump Bacterial Infection Endocrinology
    Vonoprazan hydrochloride, a proton pump inhibitor (PPI), is a potent and orally active potassium-competitive acid blocker (P-CAB), with antisecretory activity. Vonoprazan hydrochloride inhibits H +,K +-ATPase activity in porcine gastric microsomes with an IC50 of 19 nM at pH 6.5. Vonoprazan hydrochloride is developed for the research of acid-related diseases, such as gastroesophageal reflux disease and peptic ulcer disease. Vonoprazan hydrochloride can be used for eradication of Helicobacter pylori .
    Vonoprazan hydrochloride
  • HY-100007
    Vonoprazan
    5 Publications Verification

    TAK-438 free base

    Proton Pump Bacterial Endocrinology
    Vonoprazan (TAK-438 free base), a proton pump inhibitor (PPI), is a potent and orally active potassium-competitive acid blocker (P-CAB), with antisecretory activity. Vonoprazan inhibits H +,K +-ATPase activity in porcine gastric microsomes with an IC50 of 19 nM at pH 6.5. Vonoprazan is developed for the research of acid-related diseases, such as gastroesophageal reflux disease and peptic ulcer disease. Vonoprazan can be used for eradication of Helicobacter pylori .
    Vonoprazan
  • HY-124819

    Bacterial Infection
    D13-9001 is a potent AcrB (AcrAB-TolC efflux pump subunit) and MexB (MexAB-OprM efflux pump subunit) inhibitor with the KD values of 1.15 μM and 3.57 μM in E. coli and P. aeruginosa, respectively . D13-9001 exhibits antibiotic activities .
    D13-9001
  • HY-157533

    Bacterial Others
    AcrB-IN-5 (compound 8) inhibits AcrB and blocks the efflux pump in a dose-dependent manner .
    AcrB-IN-5
  • HY-100007R

    TAK-438 (Standard)

    Proton Pump Bacterial Endocrinology
    Vonoprazan (Standard) is the analytical standard of Vonoprazan. This product is intended for research and analytical applications. Vonoprazan (TAK-438 free base), a proton pump inhibitor (PPI), is a potent and orally active potassium-competitive acid blocker (P-CAB), with antisecretory activity. Vonoprazan inhibits H +,K +-ATPase activity in porcine gastric microsomes with an IC50 of 19 nM at pH 6.5. Vonoprazan is developed for the research of acid-related diseases, such as gastroesophageal reflux disease and peptic ulcer disease. Vonoprazan can be used for eradication of Helicobacter pylori .
    Vonoprazan (Standard)
  • HY-105220

    OST-766

    Proton Pump Inflammation/Immunology
    WY-47766(OST-766) is aproton pumpinhibitor .
    WY-47766
  • HY-101646

    HOE-731

    Proton Pump Cardiovascular Disease
    Saviprazole is a Proton Pump inhibitor. Saviprazole can be used in research related to gastrointestinal diseases, such as gastric ulcers and acid reflux .
    Saviprazole
  • HY-100560S

    (S)​-​(+)​-​Abscisic acid-d6; ABA-d6

    Proton Pump Metabolic Disease
    Abscisic acid-d6 is deuterium labeled Abscisic acid. Abscisic acid inhibits proton pump (H+-ATPase)[1].
    Abscisic acid-d6

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: